NextCure, a biopharmaceutical firm engaged in the discovery and development of next generation immunomedicines for cancer and other diseases, has raised $93m in Series B financing.
Gene editing company CRISPR Therapeutics and cell-based medicines and life sciences firm MaxCyte have expanded clinical and commercial license agreement into oncology.
Nestlé Health Science has increased its stake in biopharmaceutical firm Aimmune Therapeutics by making an additional equity investment of $98m.
Harpoon Therapeutics, a clinical-stage immunotherapy company engaged in the development of a class of T cell engagers, has completed $70m series C equity financing.
Recursion Pharmaceuticals, which combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs, has been given a $1.6m Phase 2 Small Business Innovation Research (SBIR) award from the National Institutes of Health (NIH) through the National Institute on Aging (NIA).
Clinical-stage biotechnology firm BioTime has signed an agreement to acquire the remaining stake in Asterias Biotherapeutics for an undisclosed sum.
US-based Brooklyn ImmunoTherapeutics, a newly formed company, has acquired the assets of IRX Therapeutics for an undisclosed price.
Shire has agreed to license exclusive worldwide rights to two rare cholestatic liver disease candidates, including the maralixibat oral inhibitor, to clinical-stage therapeutics company Mirum Pharmaceuticals.
Alexion Pharmaceuticals has wrapped up its previously announced acquisition of US-based clinical-stage biotechnology firm Syntimmune in a deal worth $1.2bn.
Gilead Sciences and Tango Therapeutics have entered into a global collaboration to discover, develop and commercialize a pipeline of targeted immuno-oncology treatments for cancer.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.